PDE5A and neoplasm: In a mouse model and in in vitro experiments on cell lines of multiple myeloma and HNSCC, the use of the phosphodiesterase-5 (PDE5) inhibitor demonstrated the down-regulation of MDSC-suppressive pathways and the consequent restoration of anti-tumor immunity [133].